Overview
For this current proposal, the investigator will conduct a single-center prospective non-randomized pilot interventional study in patients with any stage and type of cancer who are either taking at least one OACD or are taking at least one oral medication for chronic condition management in conjunction with any cancer treatment.
Primary Objective: To determine the feasibility of using a medication reminder application (Medisafe App) to improve medication adherence in cancer patients either receiving oral anticancer agents (OACDs) or receiving oral medications for chronic disease management (non-OACDs) in conjunction with non-oral cancer treatment.
Secondary Objectives: To compare and characterize medication adherence before and after the 12-week intervention using the Voils Extent of Adherence Scale and the Medisafe App. Also to determine the acceptability, utility and patient engagement with the App, to evaluate changes in healthcare related quality of life before and after the intervention, and to explore behaviors, knowledge, attitudes and beliefs related to medication adherence using a semi-structured interview delivered over the telephone.
Description
Many patients with cancer experience frustration with the large number and complex scheduling of their medications. This study will help find out how much "pill burden" exists in patients with cancer, and how a smartphone app can help patients take medications as providers prescribe. Results of this study may help figure out the best way to help patients manage medications in the future.
Eligibility
Inclusion Criteria:
- Any type/stage cancer
- Patients must be taking either:
- at least one oral anti-cancer drug (OACD) or
- at least one oral medication (non-OACD) for management of a chronic condition in addition to receiving non-oral cancer treatment
- Patients must have access to a mobile phone or tablet that can download the Medisafe
App. (ie apple/android)
- Subjects must be able to complete self-administered questionnaires in English or Spanish.
- Co-enrollment in trials involving pharmacologic therapy is allowed.
Exclusion Criteria:
- Inability to provide informed consent